Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.32032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Adam P Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Immunocompromised Host, Neoplasms. Die Arbeit nennt 23 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long‐acting monoclonal antibody approved in 2023, offers single‐dose seasonal protection. We conducted a single‐center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024–2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non‐recipients, including one RSV‐related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, Toronto, Ontario, Canada.
ORCID-Profile: Adam P Yan, Lillian Sung, Sumit Gupta
Zitieren
APA
Yan, A. P., Feng, Y., Hassanieh, D. E., Starr, A., Yi, M., Schechter-Finkelstein, T., Drynan, J., Sung, L., & Gupta, S. (2025). Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32032
Vancouver
Yan AP, Feng Y, Hassanieh DE, Starr A, Yi M, Schechter-Finkelstein T, et al. Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32032
BibTeX
@article{Yan2025,
author = {Yan, Adam P and Feng, Yuqing and Hassanieh, Dima El and Starr, Allison and Yi, Martin and Schechter-Finkelstein, Tal and Drynan, Jennifer and Sung, Lillian and Gupta, Sumit},
title = {Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.32032}
}
EUVIMED